Immunotherapy Using Autologous T Cell-Engineered With CD19-specific Chimeric Antigen Receptor for the Treatment of Recurrent /Refractory B Cell Leukemia

Inclusion Criteria: 1. Age ≥ 18 years old, male or female 2. Karnofsky≥60% 3. At least 2 courses of chemotherapy were performed 4. Creatinine is less than 2.5mg/dL;alanine aminotransferase (ALT) / aspartate aminotransferase(AST) less than 3 times of the normal bilirubin is less than 3mg/dL 5. Adequate venous access, isolation, and white blood cell production without other taboos 6. Signed informed consent 7. Patients with fertility are willing to use contraceptive method. 8. At least two months after infusion of T cells Exclusion Criteria: 1. Need to use glucocorticoid therapy 2. Need immunotherapy 3. Creatinine \> 2.5mg/dL; ALT / AST \> 5 times of the normal; bilirubin \> 3mg/dL 4. Forced expiratory volume at one second (FEV1)\<2 L,diffusing capacity of the lung for carbon monoxide (DLCO)\<40% 5. congestive cardiac failure (III or IV, NYHA); Significant hypotension; Coronary heart disease Can not be controlled; DLCO\<40% 6. human immunodeficiency virus (HIV), hepatitis B virus (HBV),hepatitis C virus (HCV) patients 7. Had received gene therapy 8. Significant encephalopathy / new focal neurologic impairment 9. Blood culture positive or radiographic evidence of infection 10. Other drugs, or other biological treatment, chemotherapy or radiotherapy are performed within a month 11. The history of allergic reactions in cell therapy and cetuximab similar compounds.